Search Results

You are looking at 1 - 10 of 148 items for :

  • "Childhood" x
  • All content x
Clear All
Full access

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group

Background Most survivors of childhood cancer experience long-term health complications due to their cancer treatment, warranting lifelong care. 1 Survivorship care provides opportunities for late effects prevention, screening, and proactive

Full access

Steven G. Waguespack and Gary Francis

history of this disease, 18 , 24 which may portend a worse prognosis and require more aggressive treatment. 25 Unique Features of Childhood Thyroid Cancers In children, the most common presentation for differentiated thyroid cancer (DTC) is that

Full access

Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff

inhibitors and PD-L1 inhibitors), it is difficult to predict how the prevalence of POI will compare in today's and tomorrow's survivors of childhood cancer. Management of Perimenopause and Menopause in Survivors POI results in the cessation of menses

Full access

Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos

neoplasms. Nonmelanoma skin cancer (NMSC), principally basal cell carcinoma (BCC), is the most common subsequent neoplasm arising in childhood cancer survivors, occurring in 1% to 9% of survivors and accounting for 41% to 58% of all subsequent neoplasms. 3

Full access

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby

” and “lymphangiomatosis” in favor of “generalized lymphatic anomaly”; the literature reflects a change in terminology. Lymphangiomatosis is often a childhood disease, but it may present in adults via infiltrating organs and cause obstruction, bleeding

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

greatest risk for these cancers. Most of these tumors develop on sun-exposed skin sites. The most common sites are on the head and neck area. According to a report from the Childhood Cancer Survivor Study, long-term survivors of childhood and adolescent

Full access

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina

many melanocytic proliferations in childhood demonstrate pathologic features showing significant overlap with both benign and malignant lesions. These diagnostically challenging lesions have been given a variety of confusing acronyms and appellations

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

increasing incidence of treatment-related myelodysplasia and leukemia in survivors of childhood tumors and young adulthood, such as Hodgkin disease, sarcomas, breast and testicular cancers, and lymphomas. Ionizing radiation and occupational exposure to

Full access

Marla L. Clayman, Maya M. Harper, Gwendolyn P. Quinn, Joyce Reinecke, and Shivani Shah

files and identify recurrent themes. Results Interviews were conducted between June 2010 and November 2011 with respondents at 30 of the 39 CCCs. Of the remaining CCCs, 4 did not respond to repeated requests, 3 referred the authors to childhood

Full access

Roswell Park Cancer Institute

Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.

For the most recent version of the guidelines, please visit